Silexion Therapeutics doses first patient in Phase 2/3 SIL204 pancreatic cancer trial

Global trial is testing SIL204 with standard chemotherapy versus chemotherapy alone in newly diagnosed KRAS-mutated, unresectable stage 3 patients. First dosing occurred at Tel Aviv Sourasky Medical Center, with additional sites in Israel and Germany moving toward activation.